Misplaced Pages

#806193

64-443: IC 50 is commonly used as a measure of antagonist drug potency in pharmacological research. IC 50 is comparable to other measures of potency, such as EC 50 for excitatory drugs . EC 50 represents the dose or plasma concentration required for obtaining 50% of a maximum effect in vivo . IC 50 can be determined with functional assays or with competition binding assays. Sometimes, IC 50 values are converted to

128-450: A single cellular response by binding to the receptor, thus initiating a biochemical mechanism for change within a cell. Antagonists were thought to turn "off" that response by 'blocking' the receptor from the agonist. This definition also remains in use for physiological antagonists , substances that have opposing physiological actions, but act at different receptors. For example, histamine lowers arterial pressure through vasodilation at

192-424: A biological response by binding to and blocking a receptor rather than activating it like an agonist . Antagonist drugs interfere in the natural operation of receptor proteins. They are sometimes called blockers ; examples include alpha blockers , beta blockers , and calcium channel blockers . In pharmacology , antagonists have affinity but no efficacy for their cognate receptors, and binding will disrupt

256-402: A bound ligand is said to display "constitutive activity". The constitutive activity of a receptor may be blocked by an inverse agonist . The anti-obesity drugs rimonabant and taranabant are inverse agonists at the cannabinoid CB1 receptor and though they produced significant weight loss, both were withdrawn owing to a high incidence of depression and anxiety, which are believed to relate to

320-421: A competition assay which would occupy 50% of the receptors if no ligand were present. The Cheng-Prusoff equation produces good estimates at high agonist concentrations, but over- or under-estimates K i at low agonist concentrations. In these conditions, other analyses have been recommended. Receptor antagonists A receptor antagonist is a type of receptor ligand or drug that blocks or dampens

384-493: A constant, weak level of activity, whether its normal agonist is present at high or low levels. In addition, it has been suggested that partial agonism prevents the adaptive regulatory mechanisms that frequently develop after repeated exposure to potent full agonists or antagonists. E.g. Buprenorphine , a partial agonist of the μ-opioid receptor , binds with weak morphine-like activity and is used clinically as an analgesic in pain management and as an alternative to methadone in

448-442: A distinctly separate binding site from the agonist, exerting their action to that receptor via the other binding site. They do not compete with agonists for binding at the active site. The bound antagonists may prevent conformational changes in the receptor required for receptor activation after the agonist binds. Cyclothiazide has been shown to act as a reversible non-competitive antagonist of mGluR1 receptor . Another example of

512-399: A non-competitive is phenoxybenzamine which binds irreversibly (with covalent bonds ) to alpha- adrenergic receptors , which in turn reduces the fraction of available receptors and reduces the maximal effect that can be produced by the agonist . Uncompetitive antagonists differ from non-competitive antagonists in that they require receptor activation by an agonist before they can bind to

576-557: A particular structure. This has been analogously compared to how locks will only accept specifically shaped keys . When a ligand binds to a corresponding receptor, it activates or inhibits the receptor's associated biochemical pathway, which may also be highly specialised. Receptor proteins can be also classified by the property of the ligands. Such classifications include chemoreceptors , mechanoreceptors , gravitropic receptors , photoreceptors , magnetoreceptors and gasoreceptors. The structures of receptors are very diverse and include

640-415: A receptor and produce physiological responses such as change in the electrical activity of a cell . For example, GABA , an inhibitory neurotransmitter , inhibits electrical activity of neurons by binding to GABA A receptors . There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases

704-410: A receptor is its binding affinity, which is inversely related to the dissociation constant K d . A good fit corresponds with high affinity and low K d . The final biological response (e.g. second messenger cascade , muscle-contraction), is only achieved after a significant number of receptors are activated. Affinity is a measure of the tendency of a ligand to bind to its receptor. Efficacy

SECTION 10

#1732783982807

768-424: A receptor. They are true antagonists, so to speak. The term was created to distinguish fully inactive antagonists from weak partial agonists or inverse agonists. Partial agonists are defined as drugs that, at a given receptor, might differ in the amplitude of the functional response that they elicit after maximal receptor occupancy. Although they are agonists, partial agonists can act as a competitive antagonist in

832-421: A right shift in the curve occurs where there is a receptor reserve similar to non-competitive antagonists. A washout step in the assay will usually distinguish between non-competitive and irreversible antagonist drugs, as effects of non-competitive antagonists are reversible and activity of agonist will be restored. Irreversible competitive antagonists also involve competition between the agonist and antagonist of

896-487: A separate allosteric binding site. This type of antagonism produces a kinetic profile in which "the same amount of antagonist blocks higher concentrations of agonist better than lower concentrations of agonist". Memantine , used in the treatment of Alzheimer's disease , is an uncompetitive antagonist of the NMDA receptor . Silent antagonists are competitive receptor antagonists that have zero intrinsic activity for activating

960-424: A shift in the log concentration–effect curve to the right, but, in general, both a decrease in slope and a reduced maximum are obtained. Receptor (biochemistry) In biochemistry and pharmacology , receptors are chemical structures, composed of protein , that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers which bind to

1024-464: Is a locally acting feedback mechanism. The ligands for receptors are as diverse as their receptors. GPCRs (7TMs) are a particularly vast family, with at least 810 members. There are also LGICs for at least a dozen endogenous ligands, and many more receptors possible through different subunit compositions. Some common examples of ligands and receptors include: Some example ionotropic (LGIC) and metabotropic (specifically, GPCRs) receptors are shown in

1088-500: Is a type of insurmountable antagonist that may act in one of two ways: by binding to an allosteric site of the receptor, or by irreversibly binding to the active site of the receptor. The former meaning has been standardised by the IUPHAR , and is equivalent to the antagonist being called an allosteric antagonist . While the mechanism of antagonism is different in both of these phenomena, they are both called "non-competitive" because

1152-420: Is an antidote to alcohol and flumazenil is an antidote to benzodiazepines . Competitive antagonists are sub-classified as reversible ( surmountable ) or irreversible ( insurmountable ) competitive antagonists, depending on how they interact with their receptor protein targets. Reversible antagonists, which bind via noncovalent intermolecular forces, will eventually dissociate from the receptor, freeing

1216-468: Is derived from anti- ("against") and agonizesthai ("to contend for a prize"). Antagonists were discovered in the 20th century by American biologist Bailey Edgren. Biochemical receptors are large protein molecules that can be activated by the binding of a ligand such as a hormone or a drug . Receptors can be membrane-bound, as cell surface receptors , or inside the cell as intracellular receptors , such as nuclear receptors including those of

1280-402: Is present. In functional assays of non-competitive antagonists, depression of the maximal response of agonist dose-response curves, and in some cases, rightward shifts, is produced. The rightward shift will occur as a result of a receptor reserve (also known as spare receptors) and inhibition of the agonist response will only occur when this reserve is depleted. An antagonist that binds to

1344-411: Is referred to as its endogenous ligand. E.g. the endogenous ligand for the nicotinic acetylcholine receptor is acetylcholine , but it can also be activated by nicotine and blocked by curare . Receptors of a particular type are linked to specific cellular biochemical pathways that correspond to the signal. While numerous receptors are found in most cells, each receptor will only bind with ligands of

SECTION 20

#1732783982807

1408-454: Is required to inhibit the maximum biological response. Lower concentrations of drugs may be associated with fewer side-effects. The affinity of an antagonist for its binding site (K i ), i.e. its ability to bind to a receptor, will determine the duration of inhibition of agonist activity. The affinity of an antagonist can be determined experimentally using Schild regression or for competitive antagonists in radioligand binding studies using

1472-466: Is the binding affinity of the inhibitor, IC 50 is the functional strength of the inhibitor, [S] is fixed substrate concentration and K m is the Michaelis constant i.e. concentration of substrate at which enzyme activity is at half maximal (but is frequently confused with substrate affinity for the enzyme, which it is not). Alternatively, for inhibition constants at cellular receptors: where [A]

1536-459: Is the fixed concentration of agonist and EC 50 is the concentration of agonist that results in half maximal activation of the receptor. Whereas the IC 50 value for a compound may vary between experiments depending on experimental conditions, (e.g. substrate and enzyme concentrations) the K i is an absolute value. K i is the inhibition constant for a drug; the concentration of competing ligand in

1600-411: Is the measure of the bound ligand to activate its receptor. Not every ligand that binds to a receptor also activates that receptor. The following classes of ligands exist: Note that the idea of receptor agonism and antagonism only refers to the interaction between receptors and ligands and not to their biological effects. A receptor which is capable of producing a biological response in the absence of

1664-573: Is where the line cuts the x-axis on the regression plot. Whereas, with Schild regression, antagonist concentration is varied in experiments used to derive K i values from the Cheng-Prusoff equation, agonist concentrations are varied. Affinity for competitive agonists and antagonists is related by the Cheng-Prusoff factor used to calculate the K i (affinity constant for an antagonist) from the shift in IC 50 that occurs during competitive inhibition . The Cheng-Prusoff factor takes into account

1728-746: The Cheng-Prusoff equation . Schild regression can be used to determine the nature of antagonism as beginning either competitive or non-competitive and K i determination is independent of the affinity, efficacy or concentration of the agonist used. However, it is important that equilibrium has been reached. The effects of receptor desensitization on reaching equilibrium must also be taken into account. The affinity constant of antagonists exhibiting two or more effects, such as in competitive neuromuscular-blocking agents that also block ion channels as well as antagonising agonist binding, cannot be analyzed using Schild regression. Schild regression involves comparing

1792-677: The histamine H 1 receptor , while adrenaline raises arterial pressure through vasoconstriction mediated by alpha -adrenergic receptor activation. Our understanding of the mechanism of drug-induced receptor activation and receptor theory and the biochemical definition of a receptor antagonist continues to evolve. The two-state model of receptor activation has given way to multistate models with intermediate conformational states. The discovery of functional selectivity and that ligand-specific receptor conformations occur and can affect interaction of receptors with different second messenger systems may mean that drugs can be designed to activate some of

1856-423: The mitochondrion . Binding occurs as a result of non-covalent interactions between the receptor and its ligand, at locations called the binding site on the receptor. A receptor may contain one or more binding sites for different ligands. Binding to the active site on the receptor regulates receptor activation directly. The activity of receptors can also be regulated by the binding of a ligand to other sites on

1920-402: The pIC 50 scale. Due to the minus sign, higher values of pIC 50 indicate exponentially more potent inhibitors. pIC 50 is usually given in terms of molar concentration (mol/L, or M), thus requiring IC 50 in units of M. The IC 50 terminology is also used for some behavioral measures in vivo, such as the two bottle fluid consumption test . When animals decrease consumption from

1984-422: The receptor theory of pharmacology stated that a drug's effect is directly proportional to the number of receptors that are occupied. Furthermore, a drug effect ceases as a drug-receptor complex dissociates. Ariëns & Stephenson introduced the terms "affinity" & "efficacy" to describe the action of ligands bound to receptors. In contrast to the accepted Occupation Theory , Rate Theory proposes that

IC50 - Misplaced Pages Continue

2048-443: The activation of receptors is directly proportional to the total number of encounters of a drug with its receptors per unit time. Pharmacological activity is directly proportional to the rates of dissociation and association, not the number of receptors occupied: As a drug approaches a receptor, the receptor alters the conformation of its binding site to produce drug—receptor complex. In some receptor systems (e.g. acetylcholine at

2112-533: The active site of a receptor is said to be "non-competitive" if the bond between the active site and the antagonist is irreversible or nearly so. This usage of the term "non-competitive" may not be ideal, however, since the term "irreversible competitive antagonism" may also be used to describe the same phenomenon without the potential for confusion with the second meaning of "non-competitive antagonism" discussed below. The second form of "non-competitive antagonists" act at an allosteric site. These antagonists bind to

2176-421: The agonist from the binding sites, resulting in a lower frequency of receptor activation. The level of activity of the receptor will be determined by the relative affinity of each molecule for the site and their relative concentrations. High concentrations of a competitive agonist will increase the proportion of receptors that the agonist occupies, higher concentrations of the antagonist will be required to obtain

2240-474: The antagonist–receptor complex, which, in turn, depends on the nature of antagonist–receptor binding. The majority of drug antagonists achieve their potency by competing with endogenous ligands or substrates at structurally defined binding sites on receptors. The English word antagonist in pharmaceutical terms comes from the Greek ἀνταγωνιστής – antagonistēs , "opponent, competitor, villain, enemy, rival", which

2304-405: The cell, and include cytoplasmic receptors and nuclear receptors . A molecule that binds to a receptor is called a ligand and can be a protein, peptide (short protein), or another small molecule , such as a neurotransmitter , hormone , pharmaceutical drug, toxin, calcium ion or parts of the outside of a virus or microbe. An endogenously produced substance that binds to a particular receptor

2368-411: The cell. 4 examples of intracellular LGIC are shown below: Many genetic disorders involve hereditary defects in receptor genes. Often, it is hard to determine whether the receptor is nonfunctional or the hormone is produced at decreased level; this gives rise to the "pseudo-hypo-" group of endocrine disorders , where there appears to be a decreased hormonal level while in fact it is the receptor that

2432-481: The change in the dose ratio, the ratio of the EC 50 of an agonist alone compared to the EC 50 in the presence of a competitive antagonist as determined on a dose response curve. Altering the amount of antagonist used in the assay can alter the dose ratio. In Schild regression, a plot is made of the log (dose ratio-1) versus the log concentration of antagonist for a range of antagonist concentrations. The affinity or K i

2496-416: The concentration needed to inhibit half of the maximum biological response of the agonist. IC 50 values can be used to compare the potency of two antagonists. IC 50 values are very dependent on conditions under which they are measured. In general, a higher concentration of inhibitor leads to lowered agonist activity. IC 50 value increases as agonist concentration increases. Furthermore, depending on

2560-410: The concentration of antagonist needed to elicit half inhibition of the maximum biological response of an agonist. Elucidating an IC 50 value is useful for comparing the potency of drugs with similar efficacies, however the dose-response curves produced by both drug antagonists must be similar. The lower the IC 50 the greater the potency of the antagonist, and the lower the concentration of drug that

2624-455: The discovery of constitutive active receptors. Antihistamines , originally classified as antagonists of histamine H 1 receptors have been reclassified as inverse agonists. Many antagonists are reversible antagonists that, like most agonists, will bind and unbind a receptor at rates determined by receptor-ligand kinetics . Irreversible antagonists covalently bind to the receptor target and, in general, cannot be removed; inactivating

IC50 - Misplaced Pages Continue

2688-420: The downstream functions of a receptor but not others. This means efficacy may actually depend on where that receptor is expressed, altering the view that efficacy at a receptor is receptor-independent property of a drug. By definition, antagonists display no efficacy to activate the receptors they bind. Antagonists do not maintain the ability to activate a receptor. Once bound, however, antagonists inhibit

2752-420: The drug-laced water bottle, the concentration of the drug that results in a 50% decrease in consumption is considered the IC 50 for fluid consumption of that drug. The IC 50 of a drug can be determined by constructing a dose-response curve and examining the effect of different concentrations of antagonist on reversing agonist activity. IC 50 values can be calculated for a given antagonist by determining

2816-403: The dynamic behavior of receptors have been used to gain understanding of their mechanisms of action. Ligand binding is an equilibrium process. Ligands bind to receptors and dissociate from them according to the law of mass action in the following equation, for a ligand L and receptor, R. The brackets around chemical species denote their concentrations. One measure of how well a molecule fits

2880-399: The effect of a single ligand , and integration allows the signal to be incorporated into another biochemical pathway. Receptor proteins can be classified by their location. Cell surface receptors , also known as transmembrane receptors, include ligand-gated ion channels , G protein-coupled receptors , and enzyme-linked hormone receptors . Intracellular receptors are those found inside

2944-482: The effect of altering agonist concentration and agonist affinity for the receptor on inhibition produced by competitive antagonists. Competitive antagonists bind to receptors at the same binding site (active site) as the endogenous ligand or agonist, but without activating the receptor. Agonists and antagonists "compete" for the same binding site on the receptor. Once bound, an antagonist will block agonist binding. Sufficient concentrations of an antagonist will displace

3008-459: The end-results of each are functionally very similar. Unlike competitive antagonists, which affect the amount of agonist necessary to achieve a maximal response but do not affect the magnitude of that maximal response, non-competitive antagonists reduce the magnitude of the maximum response that can be attained by any amount of agonist. This property earns them the name "non-competitive" because their effects cannot be negated, no matter how much agonist

3072-414: The following major categories, among others: Membrane receptors may be isolated from cell membranes by complex extraction procedures using solvents , detergents , and/or affinity purification . The structures and actions of receptors may be studied by using biophysical methods such as X-ray crystallography , NMR , circular dichroism , and dual polarisation interferometry . Computer simulations of

3136-431: The function of agonists , inverse agonists , and partial agonists . In functional antagonist assays, a dose-response curve measures the effect of the ability of a range of concentrations of antagonists to reverse the activity of an agonist. The potency of an antagonist is usually defined by its half maximal inhibitory concentration (i.e., IC 50 value). This can be calculated for a given antagonist by determining

3200-577: The inhibition of the constitutive activity of the cannabinoid receptor. The GABA A receptor has constitutive activity and conducts some basal current in the absence of an agonist. This allows beta carboline to act as an inverse agonist and reduce the current below basal levels. Mutations in receptors that result in increased constitutive activity underlie some inherited diseases, such as precocious puberty (due to mutations in luteinizing hormone receptors) and hyperthyroidism (due to mutations in thyroid-stimulating hormone receptors). Early forms of

3264-408: The interaction and inhibit the function of an agonist or inverse agonist at receptors. Antagonists mediate their effects by binding to the active site or to the allosteric site on a receptor, or they may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity. Antagonist activity may be reversible or irreversible depending on the longevity of

SECTION 50

#1732783982807

3328-472: The neuromuscular junction in smooth muscle), agonists are able to elicit maximal response at very low levels of receptor occupancy (<1%). Thus, that system has spare receptors or a receptor reserve. This arrangement produces an economy of neurotransmitter production and release. Cells can increase ( upregulate ) or decrease ( downregulate ) the number of receptors to a given hormone or neurotransmitter to alter their sensitivity to different molecules. This

3392-433: The presence of a full agonist , as it competes with the full agonist for receptor occupancy, thereby producing a net decrease in the receptor activation as compared to that observed with the full agonist alone. Clinically, their usefulness is derived from their ability to enhance deficient systems while simultaneously blocking excessive activity. Exposing a receptor to a high level of a partial agonist will ensure that it has

3456-437: The radioligand is then determined in the presence of a range of concentrations of other competing non-radioactive compounds (usually antagonists), in order to measure the potency with which they compete for the binding of the radioligand. Competition curves may also be computer-fitted to a logistic function as described under direct fit. In this situation the IC 50 is the concentration of competing ligand which displaces 50% of

3520-441: The receptor for the duration of the antagonist effects is determined by the rate of receptor turnover, the rate of synthesis of new receptors. Phenoxybenzamine is an example of an irreversible alpha blocker —it permanently binds to α adrenergic receptors , preventing adrenaline and noradrenaline from binding. Inactivation of receptors normally results in a depression of the maximal response of agonist dose-response curves and

3584-426: The receptor to be bound again. Irreversible antagonists bind via covalent intermolecular forces. Because there is not enough free energy to break covalent bonds in the local environment, the bond is essentially "permanent", meaning the receptor-antagonist complex will never dissociate. The receptor will thereby remain permanently antagonized until it is ubiquitinated and thus destroyed. A non-competitive antagonist

3648-423: The receptor, as in allosteric binding sites . Antagonists mediate their effects through receptor interactions by preventing agonist-induced responses. This may be accomplished by binding to the active site or the allosteric site. In addition, antagonists may interact at unique binding sites not normally involved in the biological regulation of the receptor's activity to exert their effects. The term antagonist

3712-573: The receptor, but the rate of covalent bonding differs and depends on affinity and reactivity of the antagonist. For some antagonists, there may be a distinct period during which they behave competitively (regardless of basal efficacy), and freely associate to and dissociate from the receptor, determined by receptor-ligand kinetics . But, once irreversible bonding has taken place, the receptor is deactivated and degraded. As for non-competitive antagonists and irreversible antagonists in functional assays with irreversible competitive antagonist drugs, there may be

3776-490: The same degree of binding site occupancy. In functional assays using competitive antagonists, a parallel rightward shift of agonist dose–response curves with no alteration of the maximal response is observed. Competitive antagonists are used to prevent the activity of drugs, and to reverse the effects of drugs that have already been consumed. Naloxone (also known as Narcan) is used to reverse opioid overdose caused by drugs such as heroin or morphine . Similarly, Ro15-4513

3840-440: The specific binding of the radioligand. The IC 50 value is converted to an absolute inhibition constant K i using the Cheng-Prusoff equation formulated by Yung-Chi Cheng and William Prusoff (see K i ). IC 50 is not a direct indicator of affinity , although the two can be related at least for competitive agonists and antagonists by the Cheng-Prusoff equation. For enzymatic reactions, this equation is: where K i

3904-601: The table below. The chief neurotransmitters are glutamate and GABA; other neurotransmitters are neuromodulatory . This list is by no means exhaustive. Enzyme linked receptors include Receptor tyrosine kinases (RTKs), serine/threonine-specific protein kinase, as in bone morphogenetic protein and guanylate cyclase, as in atrial natriuretic factor receptor. Of the RTKs, 20 classes have been identified, with 58 different RTKs as members. Some examples are shown below: Receptors may be classed based on their mechanism or on their position in

SECTION 60

#1732783982807

3968-525: The treatment of opioid dependence. An inverse agonist can have effects similar to those of an antagonist, but causes a distinct set of downstream biological responses. Constitutively active receptors that exhibit intrinsic or basal activity can have inverse agonists, which not only block the effects of binding agonists like a classical antagonist but also inhibit the basal activity of the receptor. Many drugs previously classified as antagonists are now beginning to be reclassified as inverse agonists because of

4032-433: The type of inhibition, other factors may influence IC 50 value; for ATP dependent enzymes, IC 50 value has an interdependency with concentration of ATP, especially if inhibition is competitive . In this type of assay, a single concentration of radioligand (usually an agonist) is used in every assay tube. The ligand is used at a low concentration, usually at or below its K d value. The level of specific binding of

4096-432: Was originally coined to describe different profiles of drug effects. The biochemical definition of a receptor antagonist was introduced by Ariens and Stephenson in the 1950s. The current accepted definition of receptor antagonist is based on the receptor occupancy model . It narrows the definition of antagonism to consider only those compounds with opposing activities at a single receptor. Agonists were thought to turn "on"

#806193